About: Using IL‐2R/lymphocytes for predicting the clinical progression of patients with COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Using IL‐2R/lymphocytes for predicting the clinical progression of patients with COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Using IL‐2R/lymphocytes for predicting the clinical progression of patients with COVID‐19
Creator	Wang, Feng Wang, Z Wang, F Huang, H Liu, W Luo, Y Tang, G Wu, S Sun, Sun, Z Zhang, B Hou, H Mao, L
Source	Medline; PMC; WHO
abstract	Effective laboratory markers for the estimation of disease severity and predicting the clinical progression of coronavirus disease‐2019 (COVID‐19) is urgently needed. Laboratory tests, including blood routine, cytokine profiles and infection markers, were collected from 389 confirmed COVID‐19 patients. The included patients were classified into mild (n = 168), severe (n = 169) and critical groups (n = 52). The leukocytes, neutrophils, infection biomarkers [such as C‐reactive protein (CRP), procalcitonin (PCT) and ferritin] and the concentrations of cytokines [interleukin (IL)‐2R, IL‐6, IL‐8, IL‐10 and tumor necrosis factor (TNF)‐α] were significantly increased, while lymphocytes were significantly decreased with increased severity of illness. The amount of IL‐2R was positively correlated with the other cytokines and negatively correlated with lymphocyte number. The ratio of IL‐2R to lymphocytes was found to be remarkably increased in severe and critical patients. IL‐2R/lymphocytes were superior compared with other markers for the identification of COVID‐19 with critical illness, not only from mild but also from severe illness. Moreover, the cytokine profiles and IL‐2R/lymphocytes were significantly decreased in recovered patients, but further increased in disease‐deteriorated patients, which might be correlated with the outcome of COVID‐19. Lymphopenia and increased levels of cytokines were closely associated with disease severity. The IL‐2R/lymphocyte was a prominent biomarker for early identification of severe COVID‐19 and predicting the clinical progression of the disease.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.1111/cei.13450
bibo:pmid	32365221
has license	no-cc
sha1sum (hex)	ba52a6ce5b2306473a005e7bfde63e52713061ed
schema:url	https://doi.org/10.1111/cei.13450
resource representing a document's title	Using IL‐2R/lymphocytes for predicting the clinical progression of patients with COVID‐19
has PubMed Central identifier	PMC7267633
has PubMed identifier	32365221
schema:publication	Clin Exp Immunol
resource representing a document's body	covid:ba52a6ce5b2306473a005e7bfde63e52713061ed#body_text
is schema:about of	named entity 'Lymphopenia' named entity 'critical' named entity 'prominent' named entity 'concentrations' named entity 'predicting' named entity 'patients' named entity 'lymphocytes' named entity 'INCLUDING' named entity 'COVID-19' named entity 'IL-2R' named entity 'PROTEIN ' named entity 'DISEASE' named entity 'SEVERE COVID-19' named entity 'CLASSIFIED' named entity 'CORRELATED' named entity 'WAS A' named entity 'POSITIVELY CORRELATED' named entity 'DETERIORATED' named entity 'RECOVERED' named entity 'ESTIMATION' named entity 'CYTOKINE ' named entity 'ASSOCIATED WITH' named entity 'correlated' named entity 'cytokines' named entity 'illness' named entity 'classified' named entity 'tests' named entity 'estimation' named entity 'number' named entity 'IL-2R' named entity 'disease' named entity 'superior' named entity 'IL-2R' named entity 'lymphocytes' named entity 'patients' named entity 'disease' named entity 'Laboratory' named entity 'IL-2R' named entity 'coronavirus disease' named entity 'interleukin' named entity 'lymphocytes' named entity 'lymphocytes' named entity 'critical illness' named entity 'CRP' named entity 'respiration' named entity 'lymphocytes' named entity 'C-reactive protein' named entity 'CD25' named entity 'acute lung injury' named entity 'lymphocytes' named entity 'viral infection' named entity 'RNA' named entity 'Odds ratios' named entity 'TNF-α' named entity 'nucleoprotein' named entity 'lymphocytes' named entity 'IL-2R' named entity 'fraction of inspired oxygen' named entity 'biomarkers' named entity 'ICU' named entity 'lymphocytes' named entity 'statistically significant' named entity 'IL-6' named entity 'Shanghai' named entity 'coronavirus' named entity 'logistic regression' named entity 'IL-8' named entity 'TNF-α' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software